Hospitalizations Lower in Pulmonary Arterial Hypertension Patients Receiving Selexipag or Treprostinil

An empty hospital foyer.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.

Real-world hospitalization rates in patients taking selexipag or treprostinil for pulmonary arterial hypertension showed that selexipag is associated with lower hospitalization rates, according to the results of a recent study published in Pulmonary Circulation.

Administrative claims from patients with pulmonary arterial hypertension taking either selexipag or treprostinil were retrospectively analyzed from the Optum Clinformatics Data Mart database. Patients with pulmonary hypertension were identified using diagnostic codes. To be included in the study, participants were required to be aged 18 years or older, must have received their first oral treprostinil or selexipag prescription between January 1, 2015, and September 20, 2017, and had to maintain continuous enrollment in the prior 6 months, at minimum. Patients who switched index drug were excluded.

Primary study outcomes included the risk and rates of hospitalization associated with these 2 medications.

Of the 222 patients included in the study, 99 patients were treated with oral treprostinil and 123 patients were treated with selexipag. The mean age of the entire cohort was 61 years, and 71.7% of patients were women. There was a total of 147 all-cause hospitalizations in the study cohort, 134 of which were considered pulmonary hypertension-related hospitalizations.

When the 2 treatment groups were compared, patients treated with selexipag had 46% lower risk of all-cause hospitalization (P =.02) and 47% lower risk for PH-related hospitalization (P =.03) compared with patients treated with oral treprostinil. Adjusted rate ratios for all-cause and pulmonary hypertension-related hospitalizations were 0.58 (95% CI, 0.39-0.87) and 0.54 (95% CI, 0.35-0.82), respectively.

The study authors wrote, “In this real-world study, selexipag was associated with a lower risk and rate of all-cause and PH-related hospitalization compared with oral treprostinil.”

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.


McConnell JW, Tsang Y, Pruett J, Iii WD. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. Pulm Circ. 2020;10(4):2045894020911831. doi:10.1177/2045894020911831